All Oncology News

Pembrolizumab obtained approval from the European Commission for subcutaneous administration for all adult indications.

NICE has recommended obecabtegene autoleucel for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Dana-Farber Cancer Institute will present numerous presentations at ASH 2025 about studies in hematologic diseases and cancers.

The FDA granted fast track designation to CLN-049 for relapsed/refractory acute myeloid leukemia.

IsoPSA has been FDA approved for use as an aid in the diagnosis of high-grade prostate cancer in men at least 50 years of age with elevated PSA levels.

Sarah Rutherford, MD, discusses emerging roles for ctDNA and MRD in lymphoma, highlighting surveillance value, personalized assays, and evolving adoption.

Read the most notable updates to the latest versions of the NCCN Clinical Practice Guidelines in Oncology across tumor types ahead of 2026.

Peter Voorhees, MD, discusses the FDA approval of daratumumab for patients with high-risk smoldering multiple myeloma.

Jose Trevino, MD, discusses how immunotherapy and precision medicine approaches may advance treatment for patients with immune-resistant PDAC.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, lung cancer, urothelial cancer, and prostate cancer.

The FDA approved a new option in resectable gastric cancer, and a new agent is under priority review in mantle cell lymphoma.

Study findings indicate potential unmet needs for early vorasidenib treatment with minimal toxicity for patients with slow-growing IDH-mutant gliomas.

Jose Trevino, MD, discusses unmet needs in PDAC, highlighting early detection and multidisciplinary care amid Pancreatic Cancer Awareness Month.

Durvalumab administered with chemoradiotherapy rather than afterwards generated no significant improvement in PFS, OS, or ORR for patients with NSCLC.

Retrospective data showed vorasidenib displayed strong disease stability in addition to being well tolerated in grade 3 or 4 IDH-mutant glioma.,

Dana-Farber Cancer Institute was awarded a $20 million grant by The Elaine and Eduardo Saverin Foundation for advancements in metastatic breast cancer.

Tiago Biachi, MD, PhD, reviews how data from the CORRECT, SUNLIGHT, and FRESCO trials inform later-line treatment selection in refractory mCRC.

Vicky Makker, MD, discusses the DESTINY-Endometrial01 trial of T-DXd plus rilvegostomig or pembrolizumab in HER2+ pMMR endometrial cancer.

Mayo Clinic researchers have found previously unknown genetic and cellular processes that occur in lung cancers that respond well to immunotherapy.

The NCCN guidelines for AML have been updated to include ziftomenib as a category 2A recommendation for NPM1-mutant, relapsed/refractory AML management.

Sonrotoclax is under priority review by the FDA for the treatment of adult patients with relapsed or refractory, BTK inhibitor–pretreated MCL.

Christine Ryan, MD, discusses the limitations of current MCL treatment strategies, advances in treatment, and the evolving role of BTK inhibition.

T-DM1 showed the lowest LVEF decline vs other HER2-targeted regimens, underscoring key differences in cardiac safety.

Experts discuss insights and considerations for identifying and managing HER2-mutated non–small cell lung cancer.

B7-H3–directed CAR T cell therapy was well-tolerated and demonstrated an acceptable safety profile in recurrent glioblastoma.

The FDA approved durvalumab plus FLOT for the perioperative treatment of resectable gastric and gastroesophageal junction cancers.

Joshua Richter, MD, discusses the evaluation of the FcRH5 x CD3 bispecific antibody in multiple myeloma.

Liso-cel was approved in the EU for relapsed/refractory MCL after at least 2 lines of therapy, including a BTK inhibitor.

Subcutaneous toripalimab generated non-inferior efficacy and safety outcomes vs the IV formulation in recurrent/metastatic non squamous NSCLC.

Roswell Park Comprehensive Cancer Center unveiled a comprehensive mobile cancer screening initiative for breast and prostate cancer.